The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.
 
Joshua Brody
No Relationships to Disclose
 
John A. Thompson
Consulting or Advisory Role - Academy for Continued Healthcare Learning; Alpine Immune Sciences; BJ Bioscience; Calithera Biosciences; Clinical Care Options/NCCN; Meeting Sites Pro; Neoleukin Therapeutics; Seagen
Research Funding - Admune Therapeutics (Inst); Agensys (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunomet (Inst); Mekanistic Therapeutics (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ryvu Therapeutics (Inst); Sotio (Inst); Trillium Therapeutics (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
 
Michelle R. Kuhne
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Research Funding - Gilead Sciences
Patents, Royalties, Other Intellectual Property - Gilead Sciences
 
Xi (Rochelle) Huang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Ellen Kwan
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Michael Petrarca
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Anees Dauki
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Indrajeet Singh
Employment - Gilead Sciences; Janssen
Stock and Other Ownership Interests - Gilead Sciences; Janssen
 
Nishanthan Rajakumaraswamy
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); Gilead Sciences; Harbour BioMed; MedTree (I); Mundipharma; Seagen; ShangPharma Innovation; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bayer